Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection

References

• Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC. 2020. ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 383:992–994. doi: https://doi.org/10.1056/NEJMc2022236
   Google Scholar
• Cai L, Sun Y, Song Y, Xu L, Bei Z, Zhang D, Dou Y, Wang H. 2017. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 162:2847–2853. doi: https://doi.org/10.1007/s00705-017-3436-8
   PubMed Web of Science ®Google Scholar
• Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, et al. 2020. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) Online.
   Google Scholar
• Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al. 2020. A trial of lopinavir-ritonavir in Adults hospitalized with severe covid-19. N Engl J Med. 382:1787–1799. doi: https://doi.org/10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL. 2014. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational rift valley fever. PLoS Negl Trop Dis. 8:e2790. doi: https://doi.org/10.1371/journal.pntd.0002790
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Q, Guo D. 2020. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 92:418–423. doi: https://doi.org/10.1002/jmv.25681
   PubMed Web of Science ®Google Scholar
• Coronavirus Disease 2019 (COVID-19). 2019. Centers for disease control and prevention. Centers for Disease Control and Prevention.
   Google Scholar
• Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, Park A, Lee B, Komeno T, Furuta Y, Freiberg AN. 2018. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep. 8:7604. doi: https://doi.org/10.1038/s41598-018-25780-3
   PubMedGoogle Scholar
• Dehelean CA, Lazureanu V, Coricovac D, Mioc M, Oancea R, Marcovici I, Pinzaru I, Soica C, Tsatsakis AM, Cretu O. 2020. SARS-CoV-2: Repurposed drugs and novel therapeutic approaches-insights into chemical structure-biological activity and toxicological screening. J Clin Med. 9:2084. doi: https://doi.org/10.3390/jcm9072084
   Google Scholar
• Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, Brichler S, Cohen Y. 2020. SARS-Cov-2 was already spreading in France in late December 2019. Int. J. Antimicrob Agents. 55:106006. doi: https://doi.org/10.1016/j.ijantimicag.2020.106006
   PubMed Web of Science ®Google Scholar
• Dong L, Hu S, Gao J. 2020. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 14:58–60. doi: https://doi.org/10.5582/ddt.2020.01012
   PubMed Web of Science ®Google Scholar
• Drabikowska AK, Dudycz L, Shugar D. 1979. Studies on the mechanism of antiviral action of 1-(beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide (ribavirin). J Med Chem. 22:653–657. doi: https://doi.org/10.1021/jm00192a009
   Google Scholar
• Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. 2020. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 6:672–683. doi: https://doi.org/10.1021/acscentsci.0c00489
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. 2015. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 1282:1–23. doi: https://doi.org/10.1007/978-1-4939-2438-7_1
   PubMedGoogle Scholar
• Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 100:446–454. doi: https://doi.org/10.1016/j.antiviral.2013.09.015
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, et al. 2002. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 46:977–981. doi: https://doi.org/10.1128/AAC.46.4.977-981.2002
   PubMed Web of Science ®Google Scholar
• Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 82:95–102. doi: https://doi.org/10.1016/j.antiviral.2009.02.198
   PubMed Web of Science ®Google Scholar
• Goldman JD, Lye DC, Hui DS, Marks KM, Bruno R, Monetjano R, Spinner CD, Galli M, Ahn MY, Nahass RG, et al. 2020. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. Online. https://doi.org/https://doi.org/10.1056/NEJMoa2015301.
   Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 295:6785–6797. doi: https://doi.org/10.1074/jbc.RA120.013679
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:271–280. doi: https://doi.org/10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Holshue ML, Debolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, et al. 2020. First case of 2019 novel coronavirus in the United States. N Engl J Med. 382:929–936. doi: https://doi.org/10.1056/NEJMoa2001191
   PubMed Web of Science ®Google Scholar
• Huang J, Song W, Huang H, Sun Q. 2020. Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19. J. Clin. Med. 9:1131. doi: https://doi.org/10.3390/jcm9041131
   Web of Science ®Google Scholar
• Ibrahim IM, Abdelmalek DH, Elshahat ME, Elfiky AA. 2020. COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect. 80:554–562. doi: https://doi.org/10.1016/j.jinf.2020.02.026
   PubMed Web of Science ®Google Scholar
• Kahn JS, McIntosh K. 2005. History and recent advances in coronavirus discovery. Pediatr Infect Dis J. 24:S223–S227. discussion S226. doi: https://doi.org/10.1097/01.inf.0000188166.17324.60
   PubMedGoogle Scholar
• Kerber R, Lorenz E, Duraffour S, Sissoko D, Rudolf M, Jaeger A, Cisse SD, Camara AM, Miranda O, Castro CM, et al. 2019. Laboratory findings, compassionate use of Favipiravir, and outcome in patients with Ebola virus disease, Guinea, 2015-A retrospective observational study. J Infect Dis. 220:195–202. doi: https://doi.org/10.1093/infdis/jiz078
   Google Scholar
• Li F. 2016. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 3:237–261. doi: https://doi.org/10.1146/annurev-virology-110615-042301
   PubMed Web of Science ®Google Scholar
• Li G, De Clercq E. 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 19:149–150. doi: https://doi.org/10.1038/d41573-020-00016-0
   PubMed Web of Science ®Google Scholar
• Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, et al. 2020. Coronavirus infections and immune responses. J Med Virol. 92:424–432. doi: https://doi.org/10.1002/jmv.25685
   PubMed Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, Mbaya OT, Proschan M, Mukadi D, Manzo ML, Nzolo D, Oloma AT, Ibanda A, et al. 2019. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 381:2293–2303. doi: https://doi.org/10.1056/NEJMoa1910993
   PubMed Web of Science ®Google Scholar
• Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J. 2013. Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmac. 84:615–629. doi: https://doi.org/10.1124/mol.113.087247
   Web of Science ®Google Scholar
• Perlman S, Netland J. 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 7:439–450. doi: https://doi.org/10.1038/nrmicro2147
   PubMed Web of Science ®Google Scholar
• Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon K3, Yount BL, Agostini ML, Stevens LJ, Chappell JD, et al. 2020. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 32:107940. doi: https://doi.org/10.1016/j.celrep.2020.107940
   PubMed Web of Science ®Google Scholar
• Savarino A, Trani LD, Donatelli I, Cauda R, Cassone A. 2006. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 6:67–69. doi: https://doi.org/10.1016/S1473-3099(06)70361-9
   PubMed Web of Science ®Google Scholar
• Smith RD. 2006. Responding to global infectious disease outbreaks: lessons from SARS on the role of risk perception, communication and management. Soc Sci Med. 63:3113–3123. doi: https://doi.org/10.1016/j.socscimed.2006.08.004
   PubMed Web of Science ®Google Scholar
• Tiwari V, Beer JC, Sankaranarayanan NV, Swanson-Mungerson M, Desai UR. 2020. Discovering small-molecule therapeutics against SARS-CoV-2. Drug Discov Today. 25:1535–1544. doi: https://doi.org/10.1016/j.drudis.2020.06.017
   PubMed Web of Science ®Google Scholar
• Vankadari N, Wilce JA. 2020. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 9:601–604. doi: https://doi.org/10.1080/22221751.2020.1739565
   PubMed Web of Science ®Google Scholar
• Velavan TP, Meyer CG. 2020. The COVID-19 epidemic. Trop Med Int Health. 25:278–280. doi: https://doi.org/10.1111/tmi.13383
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30:269–271. doi: https://doi.org/10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. 2005. Angiotensin-converting enzyme 2 (ACE2), But Not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem. 280:39353–39362. doi: https://doi.org/10.1074/jbc.M508914200
   Google Scholar
• Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 531:381–385. doi: https://doi.org/10.1038/nature17180
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2014. Case-control study to assess potential risk factors related to human illness caused by the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). 2014-03-28.
   Google Scholar
• Wu D, Wu T, Liu Q, Yang Z. 2020. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis pii:. S1201-9712(20):30123–5.
   Google Scholar
• Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A. 2016. Efficacy of favipiravir (T-705) in Rabies Postexposure Prophylaxis. J Infect Dis. 213:1253–1261. doi: https://doi.org/10.1093/infdis/jiv586
   PubMed Web of Science ®Google Scholar
• Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 2020. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science pii: eabb2762.
   Google Scholar
• Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579:270–273. doi: https://doi.org/10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. 2020. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 382:727–733. doi: https://doi.org/10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar